These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Pasanisi P; Berrino F; De Petris M; Venturelli E; Mastroianni A; Panico S Int J Cancer; 2006 Jul; 119(1):236-8. PubMed ID: 16450399 [TBL] [Abstract][Full Text] [Related]
4. Assessing breast cancer risk: evolution of the Gail Model. Bondy ML; Newman LA J Natl Cancer Inst; 2006 Sep; 98(17):1172-3. PubMed ID: 16954464 [No Abstract] [Full Text] [Related]
5. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571 [TBL] [Abstract][Full Text] [Related]
6. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. Hoque A; Lippman SM; Boiko IV; Atkinson EN; Sneige N; Sahin A; Weber DM; Risin S; Lagios MD; Schwarting R; Colburn WJ; Dhingra K; Follen M; Kelloff GJ; Boone CW; Hittelman WN Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):249-59. PubMed ID: 11303595 [TBL] [Abstract][Full Text] [Related]
7. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA; J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216 [TBL] [Abstract][Full Text] [Related]
8. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve. Kruse V; Van de Wiele C; Borms M; Maes A; Pottel H; Sathekge M; Cocquyt V Nuklearmedizin; 2014 Aug; 53(4):131-8. PubMed ID: 25100557 [TBL] [Abstract][Full Text] [Related]
9. Use of likelihood ratio computation to standardize the predictive power of noninvasive cardiovascular tests. Montori VM; Ebbert JO Mayo Clin Proc; 2000 Apr; 75(4):423-4. PubMed ID: 10761502 [No Abstract] [Full Text] [Related]
10. Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors. Chen X; Yu X; Chen J; Zhang Z; Tuan J; Shao Z; Guo X; Feng Y Cancer; 2013 Jul; 119(13):2366-74. PubMed ID: 23576181 [TBL] [Abstract][Full Text] [Related]
11. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks. Le Goff JM; Lavayssière L; Rouëssé J; Spyratos F Anticancer Res; 2000; 20(3B):2213-8. PubMed ID: 10928180 [TBL] [Abstract][Full Text] [Related]
12. Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer. Patani N; Jiang W; Mokbel K Int J Cancer; 2008 Jun; 122(11):2646. PubMed ID: 18302153 [No Abstract] [Full Text] [Related]
13. Prognostic and predictive factors in breast cancer. Jansen RL; Hillen HF; Schouten HC Neth J Med; 1997 Aug; 51(2):65-77. PubMed ID: 9286143 [No Abstract] [Full Text] [Related]
14. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. Holmberg L; Iversen OE; Rudenstam CM; Hammar M; Kumpulainen E; Jaskiewicz J; Jassem J; Dobaczewska D; Fjosne HE; Peralta O; Arriagada R; Holmqvist M; Maenpaa J; J Natl Cancer Inst; 2008 Apr; 100(7):475-82. PubMed ID: 18364505 [TBL] [Abstract][Full Text] [Related]
15. The cell cycle profile test is a prognostic indicator for breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy. Kurebayashi J; Kanomata N; Kozuka Y; Moriya T; Kikukawa N; Kawasaki Y; Harada S; Tamura S; Nakayama S; Ishihara H; Noguchi S; Sonoo H Jpn J Clin Oncol; 2011 Jun; 41(6):739-46. PubMed ID: 21527410 [TBL] [Abstract][Full Text] [Related]
16. A step in the right direction. Swain SM J Clin Oncol; 2006 Aug; 24(23):3717-8. PubMed ID: 16720679 [No Abstract] [Full Text] [Related]
17. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746 [TBL] [Abstract][Full Text] [Related]
18. Beyond the Gail model: lobular involution may help refine breast cancer risk assessment. Rowan K J Natl Cancer Inst; 2009 Feb; 101(3):134-5. PubMed ID: 19176450 [No Abstract] [Full Text] [Related]
19. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Parikh RR; Housman D; Yang Q; Toppmeyer D; Wilson LD; Haffty BG Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1056-63. PubMed ID: 18676094 [TBL] [Abstract][Full Text] [Related]
20. Recurrence rates in breast cancer patients with false-negative intraoperative evaluation of sentinel lymph nodes. Taras AR; Hendrickson NA; Lowe KA; Atwood M; Beatty JD Am J Surg; 2010 May; 199(5):625-8. PubMed ID: 20466106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]